{"nctId":"NCT01588496","briefTitle":"Trial Evaluating PCSK9 Antibody in Subjects With LDL Receptor Abnormalities","startDateStruct":{"date":"2012-04-05","type":"ACTUAL"},"conditions":["Homozygous Familial Hypercholesterolemia"],"count":58,"armGroups":[{"label":"Part A: Evolocumab","type":"EXPERIMENTAL","interventionNames":["Biological: Evolocumab"]},{"label":"Part B: Evolocumab","type":"EXPERIMENTAL","interventionNames":["Biological: Evolocumab"]},{"label":"Part B: Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Evolocumab","otherNames":["AMG 145","Repatha"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Males and females ≥ 12 to ≤ 80 years of age\n* Diagnosis of homozygous familial hypercholesterolemia\n* Stable lipid-lowering therapies for at least 4 weeks\n* LDL cholesterol ≥ 130 mg/dl (3.4 mmol/L)\n* Triglyceride ≤ 400 mg/dL (4.5 mmol/L)\n* Bodyweight of ≥ 40 kg at screening.\n\nExclusion Criteria:\n\n* LDL or plasma apheresis within 8 weeks prior to randomization\n* New York Heart Association (NYHA) class III or IV or last known left ventricular ejection fraction \\< 30%\n* Myocardial infarction, unstable angina, percutaneous coronary intervention (PCI), coronary artery bypass graft (CABG) or stroke within 3 months of randomization\n* Planned cardiac surgery or revascularization\n* Uncontrolled cardiac arrhythmia\n* Uncontrolled hypertension","healthyVolunteers":false,"sex":"ALL","minimumAge":"12 Years","maximumAge":"80 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Part A: Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) at Week 12","description":"LDL-C was quantified using the ultracentrifugation method.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-16.5","spread":"6.7"}]}]}]},{"type":"SECONDARY","title":"Part A: Change From Baseline in LDL-C at Week 12","description":"LDL-C was quantified using the ultracentrifugation method.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-70.6","spread":"32.3"}]}]}]},{"type":"SECONDARY","title":"Part A: Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 12","description":null,"paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-16.6","spread":"6.5"}]}]}]},{"type":"SECONDARY","title":"Part A: Percent Change From Baseline in Apolipoprotein B at Week 12","description":null,"paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-14.9","spread":"5.0"}]}]}]},{"type":"SECONDARY","title":"Part A: Percent Change From Baseline in the Total Cholesterol/HDL-C Ratio at Week 12","description":null,"paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-18.319","spread":"6.058"}]}]}]},{"type":"SECONDARY","title":"Part A: Percent Change From Baseline in Apolipoprotein B/Apolipoprotein A1 Ratio at Week 12","description":null,"paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-15.65","spread":"4.690"}]}]}]},{"type":"SECONDARY","title":"Part A: Percentage of Participants With 15% or Greater Reduction in LDL-C From Baseline at Week 12","description":"LDL-C was quantified using the ultracentrifugation method.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"50.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Part A: Change From Baseline in Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) at Week 12","description":null,"paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-151.3","spread":"81.7"}]}]}]},{"type":"SECONDARY","title":"Part B: Percent Change From Baseline in LDL-C at the Mean of Weeks 6 and 12","description":"LDL-C was quantified using the ultracentrifugation method.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.22","spread":"4.56"},{"groupId":"OG001","value":"-25.56","spread":"3.28"}]}]}]},{"type":"SECONDARY","title":"Part B: Percent Change From Baseline in Apolipoprotein B at Week 12","description":null,"paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.97","spread":"4.74"},{"groupId":"OG001","value":"-19.17","spread":"3.46"}]}]}]},{"type":"SECONDARY","title":"Part B: Percent Change From Baseline in Apolipoprotein B at the Mean of Weeks 6 and 12","description":null,"paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.65","spread":"4.42"},{"groupId":"OG001","value":"-20.24","spread":"3.18"}]}]}]},{"type":"SECONDARY","title":"Part B: Percent Change From Baseline in Lipoprotein (a) at Week 12","description":null,"paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.43","spread":"5.49"},{"groupId":"OG001","value":"-9.40","spread":"4.07"}]}]}]},{"type":"SECONDARY","title":"Part B: Percent Change From Baseline in Lipoprotein (a) at the Mean of Weeks 6 and 12","description":null,"paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.43","spread":"4.78"},{"groupId":"OG001","value":"-12.71","spread":"3.53"}]}]}]},{"type":"PRIMARY","title":"Part B: Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) at Week 12","description":"LDL-C was quantified using the ultracentrifugation method.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.88","spread":"5.26"},{"groupId":"OG001","value":"-23.05","spread":"3.78"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":8},"commonTop":["Upper respiratory tract infection","Influenza","Abdominal pain","Nausea","Chest pain"]}}}